Literature DB >> 12471035

Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII.

Sylvie J Lavictoire1, Doris A E Parolin, Alex C Klimowicz, John F Kelly, Ian A J Lorimer.   

Abstract

EGFRvIII is a mutant epidermal growth factor that promotes aggressive growth of glioblastomas. We made a plasmid that directed the expression of an EGFRvIII with three copies of the Flag epitope at its amino terminus. Flag-tagged EGFRvIII was expressed at the same levels as unmodified EGFRvIII, and showed the same subcellular localization. However, the Flag epitope could only be detected on EGFRvIII present in the endoplasmic reticulum; the epitope was covalently modified during trafficking of the receptor through the Golgi so that it was no longer recognized by anti-Flag antibody. This property was exploited to selectively purify nascent EGFRvIII from glioblastoma cells. Nascent EGFRvIII was found to copurify with a set of other proteins, identified by mass spectrometry as the two endoplasmic reticulum chaperones Grp94 and BiP, and the two cytosolic chaperones Hsc70 and Hsp90. The Hsp90-associated chaperone Cdc37 also co-purified with EGFRvIII, suggesting that Hsp90 binds EGFRvIII as a complex with this protein. Geldanamycin and radicicol, two chemically unrelated inhibitors of Hsp90, decreased the expression of EGFRvIII in glioblastoma cells. These studies show that nascent EGFRvIII in the endoplasmic reticulum associates with Hsp90 and Cdc37, and that the Hsp90 association is necessary to maintain expression of EGFRvIII.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12471035     DOI: 10.1074/jbc.M209494200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

Authors:  Martin McLaughlin; Koen Vandenbroeck
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

2.  Temozolomide may induce cell cycle arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma cells.

Authors:  Veli Çıtışlı; Yavuz Dodurga; Canan Eroğlu; Mücahit Seçme; Çığır Biray Avcı; N Lale Şatıroğlu-Tufan
Journal:  Tumour Biol       Date:  2015-04-03

3.  CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells.

Authors:  Massod Rahimi; Theodore A Toth; Careen K Tang
Journal:  Cancer Lett       Date:  2011-03-30       Impact factor: 8.679

4.  EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism.

Authors:  G Pines; P H Huang; Y Zwang; F M White; Y Yarden
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

Review 5.  Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.

Authors:  Gur Pines; Wolfgang J Köstler; Yosef Yarden
Journal:  FEBS Lett       Date:  2010-04-11       Impact factor: 4.124

Review 6.  Cdc37 as a co-chaperone to Hsp90.

Authors:  Stuart K Calderwood
Journal:  Subcell Biochem       Date:  2015

7.  Induction of premature senescence by hsp90 inhibition in small cell lung cancer.

Authors:  Ian J Restall; Ian A J Lorimer
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

8.  Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.

Authors:  J E Bohonowych; U Gopal; J S Isaacs
Journal:  J Oncol       Date:  2010-06-24       Impact factor: 4.375

Review 9.  Endocytosis and cancer.

Authors:  Ira Mellman; Yosef Yarden
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

10.  Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.

Authors:  Bin Chen; Wei Wei; Li Ma; Bin Yang; Ryan M Gill; Mei-Sze Chua; Atul J Butte; Samuel So
Journal:  Gastroenterology       Date:  2017-03-08       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.